Cargando…
Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694688/ https://www.ncbi.nlm.nih.gov/pubmed/36422187 http://dx.doi.org/10.3390/medicina58111649 |
_version_ | 1784837865529671680 |
---|---|
author | Zekri-Nechar, Khaoula Barberán, José Zamorano-León, José J. Durbán, María Andrés-Castillo, Alcira Navarro-Cuellar, Carlos López-Farré, Antonio López-de-Andrés, Ana Jiménez-García, Rodrigo Martínez-Martínez, Carlos H. |
author_facet | Zekri-Nechar, Khaoula Barberán, José Zamorano-León, José J. Durbán, María Andrés-Castillo, Alcira Navarro-Cuellar, Carlos López-Farré, Antonio López-de-Andrés, Ana Jiménez-García, Rodrigo Martínez-Martínez, Carlos H. |
author_sort | Zekri-Nechar, Khaoula |
collection | PubMed |
description | Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. |
format | Online Article Text |
id | pubmed-9694688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96946882022-11-26 Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients Zekri-Nechar, Khaoula Barberán, José Zamorano-León, José J. Durbán, María Andrés-Castillo, Alcira Navarro-Cuellar, Carlos López-Farré, Antonio López-de-Andrés, Ana Jiménez-García, Rodrigo Martínez-Martínez, Carlos H. Medicina (Kaunas) Article Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. MDPI 2022-11-15 /pmc/articles/PMC9694688/ /pubmed/36422187 http://dx.doi.org/10.3390/medicina58111649 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zekri-Nechar, Khaoula Barberán, José Zamorano-León, José J. Durbán, María Andrés-Castillo, Alcira Navarro-Cuellar, Carlos López-Farré, Antonio López-de-Andrés, Ana Jiménez-García, Rodrigo Martínez-Martínez, Carlos H. Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients |
title | Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients |
title_full | Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients |
title_fullStr | Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients |
title_full_unstemmed | Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients |
title_short | Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients |
title_sort | analysis of prior aspirin treatment on in-hospital outcome of geriatric covid-19 infected patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694688/ https://www.ncbi.nlm.nih.gov/pubmed/36422187 http://dx.doi.org/10.3390/medicina58111649 |
work_keys_str_mv | AT zekrinecharkhaoula analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT barberanjose analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT zamoranoleonjosej analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT durbanmaria analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT andrescastilloalcira analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT navarrocuellarcarlos analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT lopezfarreantonio analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT lopezdeandresana analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT jimenezgarciarodrigo analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients AT martinezmartinezcarlosh analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients |